Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Board committee debates AB 19 90’s limits on compounding GLP‑1 weight‑loss drugs after safety concerns and industry objections
Summary
The policy committee reviewed AB 19 90, which would impose sourcing, testing and advertising restrictions on compounded GLP‑1 products and attach mandatory penalties; board staff and public commenters split over whether the bill duplicates existing law, leaves regulatory gaps and unduly curtails pharmacist judgment. The committee opted to watch and seek author engagement.
The California State Board of Pharmacy policy committee spent the longest portion of its meeting on AB 19 90, a bill amended to curb unsafe or illicit active pharmaceutical ingredients entering the compounding supply chain—particularly for GLP‑1 weight‑loss drug compounding.
As amended, AB 19 90 would prohibit selling or distributing compounded drugs containing specified GLP‑1 or related substances unless the compounder documents pharmaceutical‑grade sourcing and testing; it would require recordkeeping, authorize board inspections of compounders and suppliers, ban misleading advertising, and make violations subject to license revocation and fines of $1,000 per dose sold or distributed.
Board staff and several members expressed concern that the bill does not apply uniformly across settings where compounding occurs, such as…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
